Skip to main content
. Author manuscript; available in PMC: 2016 Nov 1.
Published in final edited form as: Obstet Gynecol. 2015 Nov;126(5):954–961. doi: 10.1097/AOG.0000000000001095

Table 2.

Presentation, latency, and neonatal morbidity by number of tocolytics received.

Tocolytic
Regimen
n Median (IQR)
Gestational Age
at Presentation
(weeks)
Median (IQR)
Cervical
Dilation at
Presentation
(cm)
Median (IQR)
Gestational
Age at Delivery
(weeks)
Latency
of >= 48
hours (n,
%)
Major
neonatal
morbidity
(n, %)
No tocolysis 64 29.8
(27.6 – 31.1)
6
(4.5 – 6.5)
29.9
(27.9 – 31.2)
5 (7.8) 28 (43.8)
Any one tocolytic* 123 29.4
(27.6 – 31.1)
5
(4 – 6)
29.9
(26.4 – 31.1)
24
(19.5)*
51 (41.5)
Any two tocolytics* 88 28.0
(25.6 – 30.4)*
4.5
(4 – 5)
28.9
(26.1 – 31.7)
25
(28.4)
40 (45.5)
Three tocolytics* 22 28.7
(26.5 – 30.4)
4
(4 – 5)
29.0
(26.7 – 31.7)
6 (27.3) 6 (27.3)
p-value 0.087 <0.001 0.566 0.014 0.482
*

Studied tocolytics: indomethacin, magnesium sulfate, nifedipine.

indicates p<0.05 in pairwise comparison with ‘no tocolysis’ group as referent.